Table 3.
Study on the in vivo activity of flavonoids.
Compound | In Vivo Models | Conc. | Effects | Mechanism of Action | References |
---|---|---|---|---|---|
Baicalin | Male C57BL/6 mice | 21 mg/kg | Arthritis | Antagonism of Th-17 cells | [140] |
Female BALB/C nude mice | 200 mg/kg | Breast cancer | Inhibits breast cancer cell proliferation and induces G1/S arrest in cells |
[131] | |
Six-week-old male C57BL/6J mice | 21 mg/kg | Diabetes | Activates AKT/AS160/GLUT4 pathway | [141] | |
Baicalein | Male SD rats | 200 mg/kg | COVID-19 | Inhibits virus replication in vivo and reduces serum levels of IL-1β and TNF-α | [133] |
Male ICR mice | 1, 5, and 10 mg/kg | Colorectal cancer | Induction of apoptosis in human colon cancer cells | [134] | |
Female C57BL/6 mice | 0.8 mg/mouse nine times | Bladder cancer | Reduces expression of cyclin D1 by inhibiting new protein synthesis and promoting proteasomal degradation and reduces expression of cyclin B1 by inhibiting new protein synthesis. | [142] | |
Male C57BL/6 mice | 0.5 mg/kg | Type 2 diabetes | Improves the viability and insulin secretion of fine beta cells and human pancreatic islets | [143] | |
Luteolin | Male ICR mice | 100 mg/kg | Acute pancreatitis | Suppresses the activation of the NF-κB pathway | [144] |
Male BALB/cN mice | 5mg/kg | Nephrotoxicity | Reduces Pt accumulation in the kidney to improve oxidative stress and inflammation | [145] | |
BALB/c nude mice | 40 mg/kg | Gastric carcinoma | Downregulates VEGF-A and MMP-9 and decreases the immune response | [146] | |
EGCG | Male C57BL/6 mice | 10 mg/kg | SARS-CoV-2 | Inhibits virus replication | [114] |
Male ICR mice | 100 mg/kg | Diabetic nephropathy | Inhibits increased OPN expression, reduces serum creatinine, and causes proteinuria and normalized morphological changes in STZ-induced diabetic nephropathy | [147] | |
Oroxylin A | Female BALB/c nude mice | 200 mg/kg | Lung cancer | Inhibits the activation of ERK signaling and inhibits snail protein content and EMT |
[93] |
Male DBA/1 mice | 10 mg/kg | Rheumatoid arthritis | Reduces serum levels of anti-CII Abs, IL-1β, IL-6, TNFα, and IL-17 | [61] | |
Tiliroside | Male C57BL/6 mice | 5 mg/kg, 15 mg/kg, 300 mg/kg Dose-dependent manner |
Type 2 diabetes | Regulates miR-27 expression and inhibits glycoisomerization | [148] |
Biochanin A | Male C57BL/6 mice | 12.5, 25, and 50 mg/kg | Acute lung injury | Inhibits TLR4/NF-κB signaling pathway activation and increases PPAR-γ expression in the lungs | [126] |
Isorhamnetin | Male ICR mice | 1 nM | Diabetes | Activates JAK/STAT pathway to increase glucose uptake by muscle cells | [149] |
Quercetin | Male ICR mice | 0.1 nM and 1 nM | Diabetes | Activates CaMKKβ/AMPK signaling pathway and activates IRS3/PI10K/Akt signaling |
[149] |
Naringenin | Pregnant Sprague–Dawley rats | 25, 50, or 100 mg/kg | Neuroapoptosis | Regulates PI3/Akt/PTEN signaling pathway and inhibits NF-κB-mediated inflammation |
[150] |